← Leaderboards
Hui-Kuan Lin
Duke University
$13,610,941
Attributed
$14,567,135
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,567,135 · 9
By mechanism
R01$14,339,384 · 8
P30$227,751 · 1
Top collaborators
- Hong-Yu Li4 shared
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionMalignant NeoplasmsMediatingTumorInnovationInsightTumorigenesisTherapeutic TargetCellsCancer TherapyOncogenicComplexUbiquitinationLinkTumor ProgressionIn VivoMouse ModelRegulationPlayGeneticUbiquitin-Protein LigasePhosphotransferasesOverexpressionNeoplasm Metastasis
Grant awards (48)
Drug Development of Skp2 PROTACs in Cancer$643,253
R01 · FY2025 · CA
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance$521,160
R01 · FY2025 · CA · contact PI
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer$513,120
R01 · FY2025 · CA · contact PI
Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer$467,627
R01 · FY2025 · CA · contact PI
Drug Development of Skp2 PROTACs in Cancer$611,086
R01 · FY2024 · CA
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance$495,102
R01 · FY2024 · CA · contact PI
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer$491,137
R01 · FY2024 · CA · contact PI
Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer$446,973
R01 · FY2024 · CA · contact PI
Drug Development of Skp2 PROTACs in Cancer$658,049
R01 · FY2023 · CA
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance$506,358
R01 · FY2023 · CA · contact PI
Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer$485,743
R01 · FY2023 · CA · contact PI
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer$400,890
R01 · FY2023 · CA · contact PI
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer$111,223
R01 · FY2023 · CA · contact PI
Drug Development of Skp2 PROTACs in Cancer$1
R01 · FY2023 · CA
Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance$497,437
R01 · FY2022 · CA · contact PI
Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer$462,843
R01 · FY2022 · CA · contact PI
Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer$498,578
R01 · FY2021 · CA · contact PI
Signaling and Biotechology Program$34,767
P30 · FY2021 · CA · contact PI
Signaling and Biotechology Program$34,569
P30 · FY2020 · CA · contact PI
Identification of a new strategy for cancer therapy$343,925
R01 · FY2019 · CA · contact PI
Signaling and Biotechology Program$93,518
P30 · FY2019 · CA · contact PI
Signaling and Biotechology Program$29,410
P30 · FY2019 · CA · contact PI
Signaling and Biotechology Program$14,689
P30 · FY2019 · CA · contact PI
Signaling and Biotechology Program$11,763
P30 · FY2019 · CA · contact PI
Signaling and Biotechology Program$5,639
P30 · FY2019 · CA · contact PI
Signaling and Biotechology Program$3,396
P30 · FY2019 · CA · contact PI
Identification of a new strategy for cancer therapy$354,563
R01 · FY2018 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$321,625
R01 · FY2018 · CA · contact PI
Identification of a new strategy for cancer therapy$354,563
R01 · FY2017 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$321,625
R01 · FY2017 · CA · contact PI
Identification of a new strategy for cancer therapy$354,563
R01 · FY2016 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$311,250
R01 · FY2016 · CA · contact PI
Identification of a new strategy for cancer therapy$354,563
R01 · FY2015 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$321,625
R01 · FY2015 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$10,375
R01 · FY2015 · CA · contact PI
Identification of a new strategy for cancer therapy$5,999
R01 · FY2015 · CA · contact PI
Novel posttranslational modification in LKB1 activation and cancer development$332,000
R01 · FY2014 · CA · contact PI
Regulation of Akt signaling activation by polyubiquitination$308,475
R01 · FY2014 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$284,775
R01 · FY2014 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$23,250
R01 · FY2014 · CA · contact PI
Regulation of Akt signaling activation by polyubiquitination$298,934
R01 · FY2013 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$298,934
R01 · FY2013 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$318,015
R01 · FY2012 · CA · contact PI
Regulation of Akt signaling activation by polyubiquitination$318,015
R01 · FY2012 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$318,015
R01 · FY2011 · CA · contact PI
Regulation of Akt signaling activation by polyubiquitination$318,015
R01 · FY2011 · CA · contact PI
The crosstalk between the PI3K/Akt signal and Skp2 in prostate cancer progression$327,850
R01 · FY2010 · CA · contact PI
Regulation of Akt signaling activation by polyubiquitination$327,850
R01 · FY2010 · CA · contact PI